70 | Imatinib Mesylate (Gleevec)FDA Link
10/2017
-
01/2000 |
22 | ruxolitinibIBA
01/2022
-
03/2012 |
21 | Tyrosine Kinase InhibitorsIBA
01/2022
-
01/2003 |
17 | Phosphotransferases (Kinase)IBA
12/2019
-
01/2003 |
15 | Proteins (Proteins, Gene)FDA Link
02/2021
-
03/2002 |
15 | Interferon-alpha (Interferon Alfa)IBA
04/2015
-
01/2000 |
9 | fedratinibIBA
01/2022
-
03/2011 |
9 | bcr-abl Fusion ProteinsIBA
11/2013
-
01/2000 |
8 | Janus Kinase InhibitorsIBA
01/2022
-
04/2013 |
7 | InterferonsIBA
12/2021
-
06/2003 |
7 | ponatinibIBA
11/2021
-
11/2012 |
7 | CytokinesIBA
01/2021
-
07/2003 |
7 | Dasatinib (BMS 354825)FDA Link
01/2018
-
10/2005 |
7 | Pharmaceutical PreparationsIBA
06/2015
-
05/2002 |
6 | Deubiquitinating EnzymesIBA
02/2021
-
11/2010 |
5 | Janus Kinase 2IBA
05/2021
-
12/2013 |
5 | DNA (Deoxyribonucleic Acid)IBA
04/2021
-
12/2010 |
5 | Transcription Factors (Transcription Factor)IBA
02/2021
-
08/2003 |
5 | Biological ProductsIBA
01/2021
-
12/2003 |
5 | Janus Kinase 1IBA
01/2018
-
10/2013 |
5 | degrasynIBA
06/2015
-
04/2007 |
5 | Cytarabine (Cytosar-U)FDA LinkGeneric
09/2005
-
05/2002 |
4 | Janus KinasesIBA
01/2022
-
03/2012 |
4 | NF-kappa B (NF-kB)IBA
01/2021
-
08/2003 |
4 | Lipase (Acid Lipase)FDA Link
12/2019
-
11/2012 |
3 | 11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA
01/2022
-
01/2018 |
3 | RNA (Ribonucleic Acid)IBA
04/2021
-
11/2011 |
3 | Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2021
-
07/2014 |
3 | Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2020
-
11/2013 |
3 | ErythropoietinFDA Link
10/2013
-
04/2002 |
3 | Reticulin (Reticular Fiber)IBA
08/2005
-
07/2004 |
3 | Hemoglobins (Hemoglobin)IBA
05/2005
-
04/2002 |
2 | LigandsIBA
10/2019
-
12/2003 |
2 | Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2019
-
08/2003 |
2 | glasdegibIBA
06/2019
-
01/2019 |
2 | Interleukin-6 (Interleukin 6)IBA
01/2019
-
02/2002 |
2 | INCB039110IBA
01/2018
-
01/2017 |
2 | nilotinibFDA Link
01/2018
-
01/2007 |
2 | Proteasome InhibitorsIBA
01/2016
-
08/2014 |
2 | marizomibIBA
01/2016
-
08/2014 |
2 | Bortezomib (Velcade)FDA Link
08/2014
-
10/2009 |
2 | UbiquitinIBA
12/2011
-
08/2011 |
2 | Biomarkers (Surrogate Marker)IBA
11/2011
-
02/2008 |
2 | Tyrosine (L-Tyrosine)FDA Link
04/2008
-
10/2005 |
2 | Protein Isoforms (Isoforms)IBA
12/2006
-
01/2004 |
2 | TransferasesIBA
01/2006
-
03/2003 |
2 | DecitabineFDA Link
06/2005
-
08/2003 |
2 | tipifarnib (R115777)IBA
12/2003
-
03/2003 |
2 | Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
12/2003
-
02/2002 |
2 | Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
12/2003
-
07/2003 |
2 | HomoharringtonineIBA
09/2003
-
04/2002 |
1 | Interleukin-1 Receptor-Associated KinasesIBA
01/2022 |
1 | AntigensIBA
12/2021 |
1 | EnzymesIBA
02/2021 |
1 | Ubiquitin-Specific ProteasesIBA
02/2021 |